Study S001030

A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02586831
Acronym: DIPIT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: TRIPLE
Status: WITHDRAWN
Enrollment: 0
Start: 2024-06-01
Primary completion: 2024-06-01
Lead sponsor: Camillo Ricordi and Jay Skyler
Conditions: Diabetes Mellitus, Type 1; Hypoglycemia; Autoimmune Diseases; Diabetes Mellitus
Interventions: DRUG:Anti-Thymocyte Globulin (ATG); DRUG:Interleukin 2; DRUG:Exenatide; DRUG:Adalimumab; OTHER:ATG Placebo; OTHER:IL-2 Placebo; OTHER:Adalimumab Placebo; OTHER:Exenatide Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Simulated C-peptide AUC [1 Year Visit]
Proportion of regulatory T cells [1 Year Visit]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.